Sugi Predict

Sugi Predict / Compounds / SCHEMBL1804258

SCHEMBL1804258

SCHEMBL1804258

NS(=O)(=O)c1ccccc1CO

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 11/20 0.50
▸ CA1 P00915 10/20 0.50
▸ CA9 Q16790 8/20 0.50
▸ CA12 O43570 5/20 0.50
▸ CA6 P23280 4/20 0.50
▸ CA5A P35218 4/20 0.50
▸ CA4 P22748 3/20 0.50
▸ CA7 P43166 3/20 0.50
▸ CA5B Q9Y2D0 3/20 0.50
▸ CA14 Q9ULX7 2/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ LDHA P00338 1/20 0.48
▸ CDK2 P24941 1/20 0.48
▸ CYP2D6 P10635 1/20 0.45
▸ PTGES2 Q9H7Z7 1/20 0.41
▸ ADRB2 P07550 1/20 0.40
▸ ADRB1 P08588 1/20 0.40
▸ ADRB3 P13945 1/20 0.40
▸ PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29704117 0.83 CA2 (0.47) CA2CA1CA9CA12CA6
SCHEMBL623822 0.83 CA2 (0.47) CA2CA1CA9CA12CA6
SCHEMBL8349565 0.82 CA2 (0.54) CA2CA1CA9CA12CA6
SCHEMBL4434908 0.82 CYP2D6 (0.56) CA12CYP2D6
SCHEMBL1809423 0.80 CDK2 (0.47) CA2CA1CA9CA12CA6
SCHEMBL31152970 0.80 CDK2 (0.47) CA2CA1CA9CA12CA6
SCHEMBL1805056 0.80 CA2 (0.49) CA2CA1CA9CA12CA6
SCHEMBL332353 0.80 CYP2D6 (0.50) CA12CDK2CYP2D6
SCHEMBL301742 0.80 CA2 (0.52) CA2CA1CA9CA12CA6
SCHEMBL1146430 0.80 CA2 (0.52) CA2CA1CA9CA12CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US claimed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US claimed
US-12630529-B2 GCN2 modulator compounds Alesta Therapeutics BV (NL) 2026-05-19 — — US disclosed
CN-113490668-B Compounds and compositions for the treatment of diseases associated with APJ receptor activity 安娜普尔纳生物股份有限公司 2025-02-25 — — CN disclosed
EP-4504720-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2025-02-12 — — EP disclosed
WO-2023196659-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-10-12 — — WO disclosed
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2023-05-11 — — US disclosed
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
EP-4107146-A1 GCN2 MODULATOR COMPOUNDS Alesta Therapeutics BV (NL) 2022-12-28 — — EP disclosed
US-11304924-B2 Pharmaceutical compositions comprising nitroxyl donors CARDIOXYL PHARMACEUTICALS, INC. (US) 2022-04-19 — — US disclosed
US-10736883-B2 Triazole furan compounds as agonists of the APJ receptor AMGEN INC. (US) 2020-08-11 — — US disclosed
WO-2018097944-A1 TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2018-05-31 — — WO disclosed
US-20150366977-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS CARDIOXYL PHARMACEUTICALS, INC. 2015-12-24 — — US disclosed
US-8404036-B2 Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2013-03-26 — — US disclosed
US-20110123784-A1 WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2011-05-26 — — US disclosed
WO-2009022171-A1 PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS ASTRAZENECA AB (SE) 2009-02-19 — — WO disclosed
EP-0946507-A1 SUBSTITUTED PYRROLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1999-10-06 — — EP disclosed
WO-1998025896-A1 SUBSTITUTED PYRROLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1998-06-18 — — WO disclosed
US-4332611-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1982-06-01 — — US disclosed
US-4332611-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1982-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630529-B2 GCN2 modulator compounds NR3C1, GCN1, EIF2AK4 CA2 1341/4885CA1 3553/4885CA9 2371/4885
US-20230143059-A1 GCN2 MODULATOR COMPOUNDS EIF2AK4, GPR119, GCN1 CA2 2579/4885CA1 4675/4885CA9 4647/4885
US-20150366977-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS TNNT2, TNNI3, NQO1 CA2 4041/4885CA1 4828/4885CA9 2604/4885
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 CA2 294/4885CA1 1974/4885CA9 3168/4885
US-20110123784-A1 WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME IK, RB1, COL1A1 CA2 1279/4885CA1 798/4885CA9 1071/4885
US-10736883-B2 Triazole furan compounds as agonists of the APJ receptor TBXA2R, AGTR1, APLNR CA2 1912/4885CA1 4059/4885CA9 2710/4885
US-11304924-B2 Pharmaceutical compositions comprising nitroxyl donors TNNT2, TNNI3, NQO1 CA2 4041/4885CA1 4828/4885CA9 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.